Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K7 | O14733 | 1/20 | 0.49 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.42 |
| ▸ | TYMP | P19971 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | CUL4A | Q13619 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.36 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.35 |
| ▸ | CDK1 | P06493 | 1/20 | 0.35 |
| ▸ | SPHK2 | Q9NRA0 | 2/20 | 0.34 |
| ▸ | SPHK1 | Q9NYA1 | 2/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 2/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2938484 | 0.84 | MAP2K7 (0.42) | MAP2K7TYMPKDM4EGAAHTT | |
| SCHEMBL3173745 | 0.81 | ADRB1 (0.45) | IRAK4TYMPKDM4EGAAHTT | |
| SCHEMBL18280176 | 0.79 | ALDH1A1 (0.52) | KDM4EGAACUL4A | |
| SCHEMBL4081189 | 0.79 | MAP2K7 (0.39) | MAP2K7TYMPKDM4EGAAHTT | |
| SCHEMBL3182216 | 0.77 | OPRK1 (0.45) | TYMPKDM4EGAAHTTCUL4A | |
| SCHEMBL359524 | 0.76 | KDM4E (0.50) | MAP2K7IRAK4TYMPKDM4EGAA | |
| SCHEMBL10208772 | 0.76 | ADRB1 (0.46) | TYMPCUL4ASPHK2SPHK1 | |
| SCHEMBL2938685 | 0.75 | MAP2K7 (0.42) | MAP2K7FFAR1SPHK2SPHK1 | |
| SCHEMBL3164051 | 0.75 | MAP2K7 (0.44) | MAP2K7TYMPCUL4AOPRK1FFAR1 | |
| SCHEMBL3169606 | 0.75 | MAP2K7 (0.39) | MAP2K7IRAK4TYMPCUL4AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100016357-A1 | Use of Beta-Aminoalcohols for the Treatment of Inflammatory Disorders and Pain | SOSEI R & D LTD. (GB) | 2010-01-21 | — | — | US | disclosed |
| EP-1993544-A1 | THE USE OF BETA-AMINOALCOHOLS FOR THE TREATMENT OF INFLAMMATORY DISORDERS AND PAIN | Sosei R&D Ltd. (GB) | 2008-11-26 | — | — | EP | disclosed |
| WO-2007102011-A1 | THE USE OF BETA-AMINOALCOHOLS FOR THE TREATMENT OF INFLAMMATORY DISORDERS AND PAIN | SOSEI R & D LTD. (GB) | 2007-09-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016357-A1 | Use of Beta-Aminoalcohols for the Treatment of Inflammatory Disorders and Pain | HRH3, HRH2, HRH1 | MAP2K7 3679/4885IRAK4 1298/4885TYMP 3775/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.